​

Day One Biopharmaceuticals Stock (NASDAQ:DAWN)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$21.53

52W Range

$5.63 - $21.53

50D Avg

$18.21

200D Avg

$10.72

Market Cap

$2.22B

Avg Vol (3M)

$4.01M

Beta

-1.75

Div Yield

-

DAWN Company Profile

Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

181

IPO Date

May 27, 2021

Website

DAWN Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24
Product$155.42M$57.22M
License$2.76M$73.94M

Fiscal year ends in Dec 25 | Currency in USD

DAWN Financial Summary

Dec 25Dec 24Dec 23
Revenue$158.18M$131.16M-
Operating Income$-127.75M$-217.27M$-206.06M
Net Income$-107.32M$-95.50M$-188.92M
EBITDA$-127.75M$-86.32M$-188.53M
Basic EPS$-1.04$-1.02$-2.37
Diluted EPS$-1.04$-1.02$-2.37

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 24, 26 | 4:30 PM
Q3 25Nov 04, 25 | 4:30 PM
Q2 25Aug 05, 25 | 4:30 PM

Peer Comparison

TickerCompany
VIRVir Biotechnology, Inc.
VALNValneva SE
RZLTRezolute, Inc.
ERASErasca, Inc.
TYRATyra Biosciences, Inc.
AVBPArriVent BioPharma, Inc. Common Stock
REPLReplimune Group, Inc.
ARVNArvinas, Inc.
GERNGeron Corporation